FIGURE 1


Tmab
mu12C4
12C4hulgG1
12C4hulgG1LALA
0.2 µg/ml
2 µg/ml
20 µg/ml
cytotoxicity (%)
100
80
60
40
20
0
increasing concentration trastuzumab from left to right (0, 0.05, 0.5 and 5 µg/ml)

FIGURE 2


% ADCC relative to trastuzumab
500
450
400
350
300
250
200
150
100
50
0
no trastuzumab
trastuzumab
trastuzumab +12C4LALA
trastuzumab+B6H12LALA
trastuzumab +1
trastuzumab + 2
trastuzumab + 3
trastuzumab + 4
trastuzumab + 5
trastuzumab + 6
trastuzumab + 7
trastuzumab + 8
trastuzumab + 9

FIGURE 3


% ADCC
50
40
30
20
10
0
No Trastuzumab
Trastuzumab
12C4-LALA
10
1
0.1
0.01
0.001
4
7
10
14
10µg/mL Trastuzumab

FIGURE 4


% ADCC
100
50
0
No Tmab
Tmab
12C4-LALA
4
7
10
13
14
15
16
10µg/mL Tmab